Varenicline-Induced Coronary Thrombosis. (December 2013)

• Record Type: Journal Article
• Authors: Kalaycı, Arzu; Eren, Aysegul; Kocabay, Gonenc; Karabay, Can Yucel; Gecmen, Cetin; Kırma, Cevat
• Is Part Of: Annals of pharmacotherapy. Volume 47:Number 12(2013)
• Page Start: 1727
• Page End: 1729
• Publication Date: 2013-12
• Subjects: varenicline -- coronary thrombosis -- acute coronary syndrome; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.5805
• DOI: 10.1177/1060028013508931
• Languages: English
• ISSNs: 1060-0280

Abstract

Varenicline (Champix, Chantix) has been available for use in smoking cessation since 2006. This drug has been associated with adverse cardiovascular events. Potential mechanisms for this association include modulation of parasymphathetic output from the brainstem to the heart, release of catecholamines and prothrombotic effect. We report the case of a 30-year-old man with no known cardiac disease, who developed thrombotic occlusion of left anterior descending artery and presented with acute coronary syndrome secondary to treatment with varenicline. The Naranjo probability scale indicates that varenicline was the probable cause of the myocardial infarction.